Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11241 clinical trials
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

metastatic hormone refractory prostate cancer
prostate cancer
metastasis
metastatic cancer
metastatic disease
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Bevacizumab - pagination testing  

Oncology

Accepts healthy volunteers
  • 0 views
  • 21 Dec, 2023
  • 3 locations
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies (Reboot-101)

This phase studies the engineered red blood cells with PD-1 inhibitor pembrolizumab(WTX212), the natural biological metabolic function of red blood cells can make the carried pembrolizumab directionally distributed in the spleen tissue and activitate T cells, suggesting that this product may solve the problem that PD-1 treatment failure.

  • 0 views
  • 01 Feb, 2023
  • 1 location
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating …

steroid-refractory pneumonitis
monoclonal antibodies
methylprednisolone
infliximab
hematologic malignancy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

The purpose of this study is to test if delaying the start of the olaparib until there is a rise in a tumor marker called CA-125 will result in a longer time until the next or different treatment for the patient's cancer. The study will also evaluate how delaying the …

cancer antigen 125
tumor markers
ovarian cancer
neutrophil count
serum bilirubin
  • 0 views
  • 05 Aug, 2020
Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases1234567 (SABR-MESCC)

This is a non-inferiority, randomised controlled trial to investigate the effect of stereotactic ablative body radiotherapy (SABR) compared to separation surgery followed by SABR in ambulatory patients with malignant epidural spinal cord compression (MESCC).The primary objective of the project is investigating the effect of SABR compared to separation surgery followed …

  • 0 views
  • 26 Sep, 2024
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

karnofsky performance status
lipase
monoclonal antibodies
renal function
serum lipase
  • 0 views
  • 05 Aug, 2020
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

endocrine therapy
fulvestrant
HER2
epidermal growth factor
hormone therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

platelet transfusion
gonadotropin
bilateral orchiectomy
ejection fraction
growth factor
  • 0 views
  • 16 Feb, 2024
  • 4 locations
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.

stereotactic body radiation therapy
adenocarcinoma of prostate
adenocarcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location